S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden's corruption knows no end (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Stocks to Buy Immediately (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden's corruption knows no end (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Stocks to Buy Immediately (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden's corruption knows no end (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Stocks to Buy Immediately (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden's corruption knows no end (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Stocks to Buy Immediately (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:GBT

Global Blood Therapeutics - GBT Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$68.49
$68.49
50-Day Range
$68.07
$68.49
52-Week Range
$21.65
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.75

GBT vs. ALKS, PRGO, ELAN, MDGL, GRFS, IONS, RXDX, CERE, ITCI, and PTCT

Should you be buying Global Blood Therapeutics stock or one of its competitors? The main competitors of Global Blood Therapeutics include Alkermes (ALKS), Perrigo (PRGO), Elanco Animal Health (ELAN), Madrigal Pharmaceuticals (MDGL), Grifols (GRFS), Ionis Pharmaceuticals (IONS), Prometheus Biosciences (RXDX), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector.

Global Blood Therapeutics vs.

Global Blood Therapeutics (NASDAQ:GBT) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.

In the previous week, Alkermes had 6 more articles in the media than Global Blood Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 0 mentions for Global Blood Therapeutics. Global Blood Therapeutics' average media sentiment score of 0.52 beat Alkermes' score of 0.19 indicating that Global Blood Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Global Blood Therapeutics Positive
Alkermes Neutral

Global Blood Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Global Blood Therapeutics presently has a consensus target price of $67.75, suggesting a potential downside of 1.08%. Alkermes has a consensus target price of $30.63, suggesting a potential upside of 8.64%. Given Alkermes' stronger consensus rating and higher probable upside, analysts plainly believe Alkermes is more favorable than Global Blood Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Blood Therapeutics
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Alkermes
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Alkermes has higher revenue and earnings than Global Blood Therapeutics. Alkermes is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$194.75 million23.73-$303.09 million-$5.01-13.67
Alkermes$1.11 billion4.17-$158.27 million-$0.96-29.36

Alkermes received 98 more outperform votes than Global Blood Therapeutics when rated by MarketBeat users. However, 71.23% of users gave Global Blood Therapeutics an outperform vote while only 71.04% of users gave Alkermes an outperform vote.

CompanyUnderperformOutperform
Global Blood TherapeuticsOutperform Votes
562
71.23%
Underperform Votes
227
28.77%
AlkermesOutperform Votes
660
71.04%
Underperform Votes
269
28.96%

Alkermes has a net margin of -14.23% compared to Global Blood Therapeutics' net margin of -137.30%. Alkermes' return on equity of -3.32% beat Global Blood Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Global Blood Therapeutics -137.30% -170.37% -39.24%
Alkermes -14.23% -3.32% -1.80%

96.2% of Alkermes shares are held by institutional investors. 4.9% of Global Blood Therapeutics shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alkermes beats Global Blood Therapeutics on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBT vs. The Competition

MetricGlobal Blood TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$4.62B$5.68B$4.46B$6.04B
Dividend YieldN/A2.64%2.43%5.45%
P/E Ratio-13.675.2487.6113.18
Price / Sales23.73284.983,591.5171.41
Price / CashN/A18.0729.0067.28
Price / Book22.464.304.625.04
Net Income-$303.09M$187.05M$115.14M$191.92M

Global Blood Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
1.3913 of 5 stars
$27.92
+2.3%
$30.63
+9.7%
+7.1%$4.59B$1.11B-29.082,280Analyst Downgrade
Short Interest ↑
PRGO
Perrigo
3.205 of 5 stars
$35.10
+1.4%
$48.00
+36.8%
-6.7%$4.74B$4.45B-36.568,900Analyst Upgrade
Short Interest ↓
Analyst Revision
ELAN
Elanco Animal Health
2.0234 of 5 stars
$9.12
+2.1%
$16.50
+80.9%
-64.0%$4.48B$4.41B-60.809,000Short Interest ↑
MDGL
Madrigal Pharmaceuticals
2.2118 of 5 stars
$238.29
-1.0%
$294.75
+23.7%
+146.9%$4.32BN/A-13.8371News Coverage
GRFS
Grifols
2.1439 of 5 stars
$7.19
+1.8%
$12.52
+74.1%
-36.9%$4.94B$6.39B0.0023,234Analyst Upgrade
News Coverage
IONS
Ionis Pharmaceuticals
2.3465 of 5 stars
$35.48
+3.5%
$45.17
+27.3%
-3.5%$5.07B$587M-18.67660
RXDX
Prometheus Biosciences
1.508 of 5 stars
$111.29
+1.5%
$136.70
+22.8%
+184.2%$5.29B$6.81M-31.9872News Coverage
CERE
Cerevel Therapeutics
1.8304 of 5 stars
$24.87
+4.3%
$34.50
+38.7%
-30.3%$3.90BN/A-10.72200Short Interest ↑
ITCI
Intra-Cellular Therapies
2.8575 of 5 stars
$56.99
+2.3%
$71.92
+26.2%
-11.5%$5.43B$250.31M-20.95512Analyst Report
Insider Selling
Short Interest ↓
News Coverage
PTCT
PTC Therapeutics
1.6646 of 5 stars
$48.19
+6.8%
$52.00
+7.9%
+29.8%$3.56B$698.80M-6.191,410Insider Selling
News Coverage
This page (NASDAQ:GBT) was last updated on 4/1/2023 by MarketBeat.com Staff